Recent Developments in Treating Indolent Non-Hodgkin’s Lymphoma (10/29)
The goal of this activity is to improve participants’ competence in implementing the most recent guideline changes and clinical advances in the management of patients with indolent non-Hodgkin’s lymphomas.
This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who provide care for patients with indolent non-Hodgkin’s lymphomas.
Upon completion of this activity, participants should be able to:
- Integrate evolving best practices emerging from clinical trials and guideline recommendations into the treatment of patients with indolent non-Hodgkin’s lymphomas
- Discuss with colleagues the unique mechanisms of action and biologic rationale for promising agents being developed with the potential to improve the current standard of care for patients with indolent non-Hodgkin’s lymphomas
- Evaluate ongoing clinical trials investigating novel therapies for patients with indolent non-Hodgkin’s lymphomas, suggesting clinical trial participation with appropriate patients
- Counsel patients on the known or preliminary safety profiles of approved or investigational agents and treatment strategies for indolent non-Hodgkin’s lymphomas
Nathan H. Fowler, MD
Associate Professor, Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician